| miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGFbeta2 signaling pathway. | miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGFβ2 signaling pathway.
Yang Z, Yang L, Sun Z, Rong Y, Bai C, Dong Q, Jian L., Free PMC Article | 11/22/2023 |
| Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression. | Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.
Yu W, Shen J, Wang X, Qin H, Xing C. | 11/15/2023 |
| The role of differentially expressed miR-660 in peripheral blood lymphocytes of patients with pulmonary tuberculosis. | The role of differentially expressed miR-660 in peripheral blood lymphocytes of patients with pulmonary tuberculosis.
Lin M, Liu M, Han X, Tao X, Tang Z, Ma Q. | 07/6/2023 |
| microRNA-660 Enhances Cisplatin Sensitivity via Decreasing SATB2 Expression in Lung Adenocarcinoma. | microRNA-660 Enhances Cisplatin Sensitivity via Decreasing SATB2 Expression in Lung Adenocarcinoma.
Wang Z, Zhou L, Chen B, Li X, Zou Q, Xu W, Fang L, Wu A, Li Z, Chen Y., Free PMC Article | 05/5/2023 |
| circITCH suppresses cell proliferation and metastasis through miR-660/TFCP2 pathway in melanoma. | circITCH suppresses cell proliferation and metastasis through miR-660/TFCP2 pathway in melanoma.
Zhang J, Cai Y, Sheng S, Zhao C, Jiang B., Free PMC Article | 06/18/2022 |
| Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression. | Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression.
Li C, Li R, Hu X, Zhou G, Jiang G. | 03/26/2022 |
| Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis. | Circ_SEC61A1 contributes to the progression of multiple myeloma cells via regulating miR-660-5p/CDK6 axis.
Luo Z, Yin Y, Tan X, Liu K, Chao Z, Xia H. | 03/5/2022 |
| Circulating status of microRNAs 660-5p and 210-3p in breast cancer patients. | Circulating status of microRNAs 660-5p and 210-3p in breast cancer patients.
Nashtahosseini Z, Aghamaali MR, Sadeghi F, Heydari N, Parsian H. | 01/22/2022 |
| Circulating miR-660-5p is associated with no-reflow phenomenon in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. | Circulating miR-660-5p is associated with no-reflow phenomenon in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Zhang J, He L., Free PMC Article | 10/23/2021 |
| Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesis. | Circ_0008305-mediated miR-660/BAG5 axis contributes to hepatocellular carcinoma tumorigenesis.
Yan F, Fan B, Wang J, Wei W, Tang Q, Lu L, Luo Z, Pu J, Yang SS., Free PMC Article | 07/24/2021 |
| MiR-660-5p promotes the progression of hepatocellular carcinoma by interaction with YWHAH via PI3K/Akt signaling pathway. | MiR-660-5p promotes the progression of hepatocellular carcinoma by interaction with YWHAH via PI3K/Akt signaling pathway.
Wu Y, Zhang Y, Wang F, Ni Q, Li M. | 03/20/2021 |
| circFBXL5 promotes breast cancer progression by sponging miR-660. | circFBXL5 promotes breast cancer progression by sponging miR-660.
Zhou H, Tang G, Zhao M, Xie L, Xie Y, Zhang Z, He X., Free PMC Article | 03/20/2021 |
| hsa_circ_0004018 suppresses the progression of liver fibrosis through regulating the hsa-miR-660-3p/TEP1 axis. | hsa_circ_0004018 suppresses the progression of liver fibrosis through regulating the hsa-miR-660-3p/TEP1 axis.
Li S, Song F, Lei X, Li J, Li F, Tan H., Free PMC Article | 03/13/2021 |
| miR-660-5p promotes breast cancer progression through down-regulating TET2 and activating PI3K/AKT/mTOR signaling. | miR-660-5p promotes breast cancer progression through down-regulating TET2 and activating PI3K/AKT/mTOR signaling.
Peng B, Li C, He L, Tian M, Li X., Free PMC Article | 01/16/2021 |
| Knockdown of miR-660 protects nucleus pulposus cells from TNF-a-induced apoptosis by targeting serum amyloid A1. | Knockdown of miR-660 protects nucleus pulposus cells from TNF-a-induced apoptosis by targeting serum amyloid A1.
Zhang HJ, Ma XH, Xie SL, Qin SL, Liu CZ, Zhang ZG., Free PMC Article | 11/21/2020 |
| miR-660, as a tumor-suppressive gene, was significantly decreased in gastric cancer and directly bound to oncogene E2F3 to inhibit E2F3 expression. | RNA N6-methyladenosine modification participates in miR-660/E2F3 axis-mediated inhibition of cell proliferation in gastric cancer.
He X, Shu Y. | 01/11/2020 |
| Our current study suggests that miR-660-5p may control Non-small cell lung cancer (NSCLC) proliferation, viability, and metastasis by targeting KLF9, which provides a potential therapeutic target for NSCLC. | Exosomal miR-660-5p promotes tumor growth and metastasis in non-small cell lung cancer.
Qi Y, Zha W, Zhang W. | 12/28/2019 |
| rescue experiments demonstrated that FOXO1 knockdown abolished the effects of miR660 knockdown on osteosarcoma (OS)cell proliferation and invasion. These results suggest that miR660 may serve oncogenic roles in OS by directly targeting FOXO1. Targeting miR660 may be an effective candidate for the treatment of patients with OS. | Downregulation of microRNA‑660 inhibits cell proliferation and invasion in osteosarcoma by directly targeting forkhead box O1.
Zhang P, Gao H, Li Q, Chen X, Wu X. | 11/3/2018 |
| This work unraveled three mRNA/miRNA networks (miR-29a-3p/TET2, miR-660-5p/EPAS1 and miR-494-3p/c-MYC) capable of affecting TKI-sensitivity in CML cells, thus leading to the design of novel targeted therapies aimed at eliminating TKI-resistant LSCs. | Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R., Free PMC Article | 04/28/2018 |
| mir-486-5p is positively regulated by mir-660-5p in lung cancer cell lines, through the mir-660-MDM2-p53 pathway. | mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis.
Borzi C, Calzolari L, Centonze G, Milione M, Sozzi G, Fortunato O., Free PMC Article | 04/29/2017 |
| Data show that miroRNA miR-660-5p can regulate the proliferation, migration, and invasion of breast cancer cells, and is a potential therapeutic target for the clinical treatment of breast cancer. | Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.
Shen Y, Ye YF, Ruan LW, Bao L, Wu MW, Zhou Y. | 03/18/2017 |
| Data show that four cardiac fibroblast-derived microRNAS miR-660-3p, miR-665, miR-1285-3p and miR-4491 were found significantly upregulated in heart and plasma during heart failure. | Identification of cardiac-related circulating microRNA profile in human chronic heart failure.
Li H, Fan J, Yin Z, Wang F, Chen C, Wang DW., Free PMC Article | 11/5/2016 |
| Importantly we report for the first time two new candidate miRNAs (miR-574-3p and miR-660-5p) as promising prognostic markers | Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O, Damaraju S., Free PMC Article | 06/28/2016 |
| Results indicate that the combination of miR-652 + miR-660 and Cyfra21-1 has the potential to help in the diagnosis of non-small cell lung carcinoma. | Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer.
Zhou C, Chen Z, Dong J, Li J, Shi X, Sun N, Luo M, Zhou F, Tan F, He J. | 11/7/2015 |
| Mir-660 inhibits lung tumorigenesis by targeting MDM2-p53 interaction. | Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino U, Sozzi G., Free PMC Article | 09/12/2015 |